Selected article for: "anti receptor antibody and cytokine release syndrome"
Author: Salvati, Lorenzo; Occhipinti, Mariaelena; Gori, Leonardo; Ciani, Luca; Mazzoni, Alessio; Maggi, Laura; Capone, Manuela; Parronchi, Paola; Liotta, Francesco; Miele, Vittorio; Annunziato, Francesco; Lavorini, Federico; Cosmi, Lorenzo
Title: Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab
  • Cord-id: t3p8srxe
  • Document date: 2020_11_5
    • ID: t3p8srxe
    Snippet: As of October 2020 management of Coronavirus disease 2019 (COVID-19) is based on supportive care and off-label or compassionate-use therapies. On March 2020 tocilizumab - an anti-IL-6 receptor monoclonal antibody - was suggested as immunomodulatory treatment in severe COVID-19 because hyperinflammatory syndrome occurs in many patients similarly to the cytokine release syndrome that develops after CAR-T cell therapy. In our retrospective observational study, 20 severe COVID-19 patients were treat
    Document: As of October 2020 management of Coronavirus disease 2019 (COVID-19) is based on supportive care and off-label or compassionate-use therapies. On March 2020 tocilizumab - an anti-IL-6 receptor monoclonal antibody - was suggested as immunomodulatory treatment in severe COVID-19 because hyperinflammatory syndrome occurs in many patients similarly to the cytokine release syndrome that develops after CAR-T cell therapy. In our retrospective observational study, 20 severe COVID-19 patients were treated with tocilizumab in addition to standard-of-care therapy (SOC) and compared with 13 COVID-19 patients receiving only SOC. Clinical respiratory status, inflammatory markers and vascular radiologic score improved after one week from tocilizumab administration. On the contrary these parameters were stable or worsened in patients receiving only SOC. Despite major study limitations, improvement of alveolar-arterial oxygen gradient as well as vascular radiologic score after one week may account for improved pulmonary vascular perfusion and could explain the more rapid recovery of COVID-19 patients receiving tocilizumab compared to controls.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and local protocol: 1, 2, 3
    • acute ards respiratory distress syndrome and low hemoglobin: 1, 2
    • acute ards respiratory distress syndrome and low hemoglobin level: 1
    • acute ards respiratory distress syndrome and low molecular: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute ards respiratory distress syndrome and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute ards respiratory distress syndrome and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute ards respiratory distress syndrome and lung edema: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung edema severe hypoxemia: 1, 2
    • acute ards respiratory distress syndrome and lung parenchyma: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • acute ards respiratory distress syndrome and lung parenchymal: 1, 2, 3, 4, 5
    • acute onset and local protocol: 1
    • acute onset and low molecular: 1, 2, 3, 4, 5
    • acute onset and low molecular weight: 1, 2, 3, 4, 5
    • acute onset and low molecular weight heparin: 1, 2, 3, 4
    • acute onset and lung edema: 1, 2, 3, 4, 5
    • acute onset and lung opacity: 1
    • acute onset and lung parenchyma: 1, 2
    • acute onset and lung parenchymal: 1
    • local protocol and low molecular: 1, 2, 3